Pacific Bio to Acquire Omniome for $800 Million in Sequencing Tie-up

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome, a San Diego short-read company, for up to $800 million. With the acquisition, PacBio will be the only company to offer highly accurate long-read and short-read sequencing programs. PacBio said combining the two technologies will expand its market and provide more value to clients. Decheng Capital, a Shanghai venture firm, led Omniome's $60 million Series B and participated in its $60 million Series C financing. More details.... Stock Symbol: (NSDQ: PACB) Share this with colleagues: // //